ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015
C-reactive protein as a marker of melanoma progression.
Abstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Predictive value of serum biomarkers for survival in melanoma: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Prognostic value of C-reactive protein in patients with melanoma: a meta-analysis.Annals of medicine · 2025Pooled it
- Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial.Nutrients · 2021Trial
- Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Trial
- Elevated C-reactive Protein Levels and Malignant Transformation Risk in Patients With Oral Mucosal Diseases.International dental journal · 2026Observational
- Prognostic Value of the Vitamin B12/C-Reactive Protein Index in Resected Stage II-III Cutaneous Melanoma: Comparison with Its Individual Components.Journal of clinical medicine · 2026Article
- Size-exclusion chromatography combined with DIA-MS enables deep proteome profiling of extracellular vesicles from melanoma plasma and serum.Cellular and molecular life sciences : CMLS · 2024Article
- Exploring the causal relationship between interleukin-6 or C reactive protein and malignant melanoma using a two-sample Mendelian randomization approach.Frontiers in oncology · 2024Review
- Association between coffee consumption and high C-reactive protein levels in Korean adults.The British journal of nutrition · 2023Article
- Review
- Article
- Longitudinal evaluation of health-related quality of life after removal of high-risk melanoma in a setting where adjuvant therapy is not available.Archives of dermatological research · 2023Article
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.Diseases (Basel, Switzerland) · 2023Review
- Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.Cancer research communications · 2023Article
- Article
- C-reactive protein: a target for therapy to reduce inflammation.Frontiers in immunology · 2023Review
- Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.Annals of medicine · 2022Article
- Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker.The Journal of investigative dermatology · 2022Article
- High C-Reactive Protein Levels Are Related to Better Survival in Patients with Uveal Melanoma.Ophthalmology science · 2022Article
- Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.Cancer immunology, immunotherapy : CII · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors at 1 institution in 1 country.
Shenying FangShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Yuling WangShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Dawen SuiShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Huey LiuShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Merrick I RossShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Jeffrey E GershenwaldShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Janice N CormierShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Richard E RoyalShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Anthony LucciShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Christopher W SchachererShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Julie M GardnerShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
John D ReveilleShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Roland L BassettShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Li-E WangShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Qingyi WeiShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Christopher I AmosShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH.
Jeffrey E LeeShenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH. jelee@mdanderson.org.
Society of Surgical Oncology · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTranslational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3MUT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7MCenter for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4MNCATS NIH HHS UL1 TR000371NCI NIH HHS P30 CA023108NCI NIH HHS P50 CA093459
Abstract
purposeTo investigate the association between blood levels of C-reactive protein (CRP) in patients with melanoma and overall survival (OS), melanoma-specific survival (MSS), and disease-free survival. PATIENTS AND
methodsTwo independent sets of plasma samples from a total of 1,144 patients with melanoma (587 initial and 557 confirmatory) were available for CRP determination. Kaplan-Meier method and Cox regression were used to evaluate the relationship between CRP and clinical outcome. Among 115 patients who underwent sequential blood draws, we evaluated the relationship between change in disease status and change in CRP using nonparametric tests.
resultsElevated CRP level was associated with poorer OS and MSS in the initial, confirmatory, and combined data sets (combined data set: OS hazard ratio, 1.44 per unit increase of logarithmic CRP; 95% CI, 1.30 to 1.59; P < .001; MSS hazard ratio, 1.51 per unit increase of logarithmic CRP; 95% CI, 1.36 to 1.68; P < .001). These findings persisted after multivariable adjustment. As compared with CRP < 10 mg/L, CRP ≥ 10 mg/L conferred poorer OS in patients with any-stage, stage I/II, or stage III/IV disease and poorer disease-free survival in those with stage I/II disease. In patients who underwent sequential evaluation of CRP, an association was identified between an increase in CRP and melanoma disease progression.
conclusionCRP is an independent prognostic marker in patients with melanoma. CRP measurement should be considered for incorporation into prospective studies of outcome in patients with melanoma and clinical trials of systemic therapies for those with melanoma.
Indexed as
AdultAgedBiomarkers, TumorCase-Control StudiesC-Reactive ProteinDisease ProgressionDNA, NeoplasmFemaleHumansKaplan-Meier EstimateMaleMelanomaMiddle AgedProportional Hazards ModelsBiomarkers, TumorC-Reactive ProteinDNA, Neoplasm
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.